Payers have decided that formularies aren't enough, at least for cancer drugs. As the <em>Wall Street Journal</em> reports, insurers are revamping their reimbursement protocols to strip incentives for pricey meds–and introduce new ones for "preferred" treatments.
written on 28.05.2014